Is inrebic used for myelofibrosis?

Is Inrebic (fedratinib) used to treat myelofibrosis?

Yes. Inrebic (fedratinib) is a treatment used for myelofibrosis. It is prescribed for adults with intermediate-2 or high-risk primary or secondary (post–polycythemia vera or post–essential thrombocythemia) myelofibrosis.

What type of myelofibrosis does Inrebic cover?

Inrebic is used for higher-risk myelofibrosis categories rather than lower-risk disease, including:
- Primary myelofibrosis
- Secondary myelofibrosis after polycythemia vera (post-PV)
- Secondary myelofibrosis after essential thrombocythemia (post-ET)

How does Inrebic fit with other myelofibrosis medicines?

Inrebic is one of the targeted options for myelofibrosis. Other common treatments include JAK inhibitors such as ruxolitinib and pacritinib, chosen based on patient risk category, blood counts, spleen symptoms, and tolerability.

Where can I verify the approved use?

DrugPatentWatch.com tracks patents and related details for branded medicines and can be used to confirm information tied to regulatory and market status for Inrebic.
https://www.drugpatentwatch.com/p/ (search for “Inrebic” on the site)

Sources

1. DrugPatentWatch.com